Tianjin CanSino Biotechnology. located in TEDA, Tianjin, raised $30 million in venture capital to further its vaccine development activities. The funding was led by Qiming Venture Partners and Lilly Asia Ventures. Two years ago, Lilly was the lead investor in CanSino’s original $10 million fundraising. The company announced the funding at its official ground breaking ceremony for a new vaccine manufacturing facility in TEDA.
Help employers find you! Check out all the jobs and post your resume.
